Pharma-Biotech Capital Construction 2015 Investment Review: $15 Billion in 2015 Project Kick-Offs
Pharma-Biotech Capital Construction 2015 Investment Review: $15 Billion in 2015 Project Kick-Offs
Attachment: pharma
SUGAR LAND--January 11, 2016--Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--With 2016 in its earliest days, let's take look back at some of the high points in 2015. A recent analysis of reported projects that began in 2015, derived from Industrial Info's Pharmaceutical-Biotech Online Database, has revealed that the North American Pharmaceutical & Biotech Industry kicked off a healthy $15 billion worth of construction activity. Within this article: Frederick, Maryland manufacturing center expansion by AstraZeneca (NYSE:AZN) and intravenous biologics plant project by Gilead Sciences (NASDAQ: GILD).
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- Food, Pharma Lift Kansas to $3 Billion in Projects Under Construction
- Kansas Sees More than $3.8 Billion in Projects Under Construction
- U.S. Power Project Spending Index Up $11.6 Billion Year Over Year in August
- McCarthy Building Companies at Work on $3.45 Billion in Projects
- M.A. Mortenson's $7 Billion in Active Projects Fueled by Windfarms, Enhance...